Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41467-023-43175-5
PubMed Identifier: 38001082
Publication URI: http://europepmc.org/abstract/MED/38001082
Type: Journal Article/Review
Volume: 14
Parent Publication: Nature communications
Issue: 1
ISSN: 2041-1723